Curriculum Vitae
 
Name:                        Lee Jia 
 
Business Address:   No. 200 Xiyuangong Rd, Institute of Oceanography, Minjiang University; University Town; Fuzhou, Fujian 350116, China;

Business Email and Phone:   pharmlink@gmail.com; 2697270856@qq.com Phone: 011-86-1515-963-0201 (mobile);  

ORCID：                    0000-0001-6839-5545；

 
EDUCATION:

PROFESSIONAL & ADMINISTRATIVE Appointments (from year 2000 due to page limitation)  
PROFESSIONAL SOCIETY AND PUBLIC SERVICE CONTRIBUTIONS:
 
1. Professional memberships and leaderships:    

• Academician, International Eurasian Academy of Sciences (IEAS; elected 2020.11.14)
• Chair, Intelligent drug section, China Pharmaceutical Society (Founding Section Chair)
• Steering Committee Member, Free Radical Biology of Medicine, Biophysical Society of China (2014-
• Member, American Association of Pharmaceutical Scientists (AAPS, 135447)
• Vice President, Fujian Pharmacological Society, China (2012-present)
• Vice-Chair and Chair (2009-2012), AAPS Drug Design & Discovery Section
• 2012 AAPS Program Coordination Committee, Award Committee
• 2011 AAPS annual meeting programming committee
• Chair-elected, and Chair (2007-2010), AAPS CRO Focus Group (600+ members)
• AAPS Nanotechnology Focus Group Steering Committee
• AAPS Fellow (elected in 2011)
• Member, American Association for Cancer Research (AACR, 75164)
• Executive Board Member, State University of New York Alumni Association (2004-2010)

 
2. Editorial services
 

1. Associate Editor, Current Drug Metabolism (2005-present);
2. Editorial Advisory Board Member, Current NanoSciences (2005-2012);
3. Future Science Editorial Advisory Board, Therapeutic Delivery (2010-present);
4. Editorial Board Member, Pharmaceutica Analytica Acta (2010-present)
5. Associate Editor, Drug Metabolism Letter (2007-2017);

 
3. Invited or ad hoc Reviewers for the following MBE-related journals:
 
1. Cell Biology & Toxicology; 2. J. Pharm. Sci; 3. Brain Research; 4. Biochem Pharmacol; 5. Letters in Drug Design & Discovery; 6. Rapid Communications in Mass Spectrometry; 7. Biopharmaceutics & Drug Disposition; 8. J. Pharm. BioMed. Anal; 9. Clinica Chimica Acta; 10. NeuroScience Letters; 11. J. Pharmacol. Exp. Ther; 12. Molecular Pharmacology; 13. Anti-Cancer Agents in Medicinal Chemistry; 14. Current Drug Metabolism; 15. Bioorganic & Medicinal Chemistry Letters; 16. Biomed Chromatog; 17. J. Chromatography; 18. Planta Medica; 19. Xenobiotics; 20. Molecular Pharmaceutics; 21. Acta Pharmacol Sin.; 22. Drug Metabolism Letter; 23. Curr. NanoScience; 24. Arch Pharmacol.; 25. Drug Metabolism and Disposition (ASPET); 26. Toxicology Letter; 27. Biomaterials (IF10.3); 28. ACS Nano (IF18). 29. Chinese Medicine; 30. Current HIV Research; 31. J. NanoSci. NanoTech. 32. Therapeutic Delivery; 33. J. Medicinal Plant Research; 34. Drug Disc. Today; 35. Current Med Chem; 36. Toxicol. Sci. 37. J. Acquired Immune Deficiency Syndromes (JAIDS); 38. The AAPS J. 39. Oncotarget; 40. Sci. Transl. Med. (IF15) 41. Chem. Sci. (IF9). 42. Nanoscale 43. ACS Applied Materials & Interfaces. 44. Theranostics. 45. J. Control. Release 46. Gut (IF17). 47. Biosensors &Bioelectr. (IF10).
Abstracts Reviewer for Annual AAPS Conferences (2008-2010).
 
GRANT REVIEW & COMMITTEE SERVICES (selected):
 
2012-2019      Grant reviewer for National Natural Science Foundation of China (NSFC)
 
07/2014        Oncology study section review site panel of NSFC, China
 
10/2014         AAPS Committee, Innovative pharmaceutical research of outstanding scientist award
 
2011-2014      Committee of the AAPS annual meeting abstract Award/ travelship
 
2013-2014      Reviewer for 2014 AAPS Research Achievement Award in Drug Discovery and                        Development Interface (DDDI)
2009-2010      Grant peer-reviewer of the South Africa Medical Research Council.
 
2005              Reviewer for 5-year NIH/NCI medical & biological contract research applications
 
Conference speaker, moderate and organizer (selected from 91 presentations):
 

1. Invited speaker, presentation title “L-Arginine increases GFR partially by nitric oxide independent mechanism via activity of agmatine”. American Society of Nephrology Annual Conference, Philadelphia, 1998/10/25.

 

2. Invited speaker, presentation title “Nitric Oxide Research: From Hypothesis to Drug Development” State University of New York at Buffalo, Nov., 2001. 

 

3. Speaker, presentation title ‘Public-private partnerships for development of 2^nd generation of ethambutol analogs for tuberculosis treatment’. Sequella, Inc. Rockville, MD, USA Dec. 2, 2003.

 

4. Invited speaker, presentation title “Nitric Oxide Research: From Hypothesis to Drug Development” in Division of Applied Pharmacology Research, OTR/OPS/CDER/FDA, USA; April, 2004. 

 

5. Speaker, Moderator and Organizer, presentation title “GLP-Regulations and Inspections in USA and China: Differences, Similarities and Case Analysis” in the two-day conference “Pharmaceutical Outsourcing: Regulations, IP, Technology, Capabilities, and Partnership” Shanghai, China, April 2-4, 2007, co-sponsored by Fudan University (SPFDU) and AAPS.

 

6. Moderator and Organizer of the symposium entitled “Exploratory IND (phase 0 trial) and its practices” at the 2007 annual National Biotechnology Conference. San Diego, CA June, 26. 2007. I designed topics and agenda, invited leaders from the FDA, NIH, and Pharmaceutics

 

7. Speaker, presented “Differences and similarities between USA and China in new drug application procedures and regulations”. Global R&D Congress, May 29-30, 2008, in Washington, DC,

 

8. Moderator, 2008 AAPS, November 19, 2008. Georgia World Congress Center, Atlanta, Georgia, USA. “Outsourcing Drug Product Development to India and China” (Roundtable).

 

9. Session Chair and Speaker, presented ‘Sino-USA collaboration: challenges and opportunities for advancing nanomedicine’, moderated a brainstorm panel session at The 1^st Joint US-China Symposium on Nanobiology and NanoMedicine, Oct. 21-23, 2008; Fragrant Hill, Beijing, China;

 

10. Moderator and Speaker: “Celebrating the Nanotechnology R&D Act: Then, Now and the Future” (Symposium), 2008 AAPS, November, 20, 2008. Georgia World Congress Center, Atlanta, Georgia, USA.

 

11. Interviewed by Pharmaceutical Technology’s Live Vidcast, Nov. 18, 2008, on “Nanotechnology in Pharmaceutical Applications”. November, 19, 2008. Georgia World Congress Center, Atlanta, Georgia, USA.

 

12. Invited Speaker: “Comparison of new drug application procedures and regulations between USA and China” at “China 2009 Pharmaceutical R&D Summit” 4th International Conference & Exhibition, April 7-9, 2009 • Grand Hyatt Hotel • Shanghai, China.

 

13. Speaker, presentation title “Anti-HIV drug development involved in ADME and nanotechnology”, and moderator at International Symposium of NanoMedicine on AIDS/HIV sponsored by Beijing University of Technology, the National Center for Nanosciences and Technology of China, AAPS, Chinese Academy of Sciences and Chinese Ministry of Science and Technology (MOST), Beijing, China; Nov.19-20, 2009.

 

14. Invited Speaker, “Contemporary understanding of the Millennium Phytomedicine― Ginseng” in Symposium: The Appalachian Center for Ethnobotanical Studies (ACES) in Tai Sophia Institute, Laurel, MD, USA; 06/26 /2010.

 

15. Invited Speaker, “The four-decade war on cancer: are we winning?” in Symposium 6: Advances of Drug Discover against cancers, The 8^th Annual Congress of International Drug Discovery Science and Technology. 10/26/2010, 9:45-10:10 am   Washington, DC. USA

 

16. Invited Speaker, “Current understanding of cancer metastasis requires changes in strategies of anticancer drug development”, in symposium 5 of annual Chinese Pharmaceutical Association Conference; Beijing, China, 11/7/2010, 9:15-9:35 am

 

17. Symposium: “Re-Engineering Nanomaterials with Biomolecules: Strategies, In Vivo Stability and Specificity, and Drugability", as both the moderator and speaker for the 2011 National Biotechnology Conference, Wednesday, May 18, 2011, at the Hilton San Francisco, CA.

 

18. Invited Speaker, “From understanding the complex of cancer metastasis to designing cancer nanomedicine: what nanomedicines can and can’t succeed” and moderator of Nano-pharmaceutics Session at the International conference of 2011 ChinaNano, at the National Convention Center, Beijing. Sept.7-9, 2011.

 

19. Designed and Chaired the Hot topic: “The heating-up of pharmaceutical globalization:  current mergers and acquisitions by Chinese Pharma in the USA and basic knowledge of laws about drug importation to China”. 10/24/2011, the Walter E. Washington Convention Center, Washington, DC. USA (attendees 500)

  

20. Session Chair, Symposium: “Global Competition and Geopolitical Priorities for Bionanotechnology R&D”. 9:00-11:00 am, Oct 25, 2011. Convention Center, Washington DC, USA. The 2011 AAPS annual conference.

 

21. Speaker, Jia: “The market and contemporary understanding of the millennium phytomedicine-ginseng” and Session Chair “Evaluating Drug Development Opportunities in Botanical Polymolecular Therapeutics”. Time: Wed. 8:30-11:00 am, 10/26/2011; Place: Washington DC convention CTR.

 

22. Invited speaker “Re-engineering PAMAM dendrimer for its multivalent binding to colon cancer cells HT29” at The 3^rd Joint US-China Symposium on Nanobiology and NanoMedicine, Dec. 5-7, 2012; Fragrant Hill, Beijing, China;

 

23. Invited speaker “Restrain activity of circulating tumor cells: the new strategy for preventing cancer from metastasis” at the China-US translational medicine international forum (250 attendees), Chinese Association of Scientists；at Guiyan Medical University, May 25, 2013.

 

24. Invited speaker “The new strategy to prevent cancer from metastasis: restrain circulating tumor cells” at the 2013 AAPS@ China Symposium, the Chinese University of Hong Kong, Aug. 17-18, 2013.

 

25. Invited speaker and Section Chair: “Nitric oxide prevents cancer metastasis by interrupting adhesion-invasion of circulating tumor cells to endothelium” in the 8th Pong Ding Yuen International Symposium on Traditional Chinese Medicine cum The 2nd International Chinese Symposium on Free Radical Research University of Hong Kong, November 14-16, 2014.

 

26. Invited speaker: “Bionanotechnology used for capturing and restraining circulating tumor cells: eliminating the suffering and death from cancer metastasis” ChinaNano 2015 meeting; Sept. 3-5, Beijing

 

27. Invited speaker: “From the 1971 Cancer Act and NCI founded to today’s global cancer therapy: cancer metastatic alert and chemoprevention”. Aug. 6-7^th 2016; Beijing; The first NIH/USA overseas returnee scholar forum.

 
30 Patents applied (17 licensed)
 
Managed and directed NIH Contract research Funding
 
1.      Southern Research Institute (NO1-CM-52203) Total budget $ 2,774,595 from 2005-2011 for preclinical antitumor and other therapeutic agent development.
 
2.      Mayo Clinic (NO1-CM-52206) Total budge $1,828,875 from 2005-2011 for preclinical pharmacological studies of antitumor and other therapeutic agents.
 
3.      University of Alabama at Birmingham (NO1-CM-52207) Total budget $ 1,714,794 from 2005-2011 for antitumor-related medical & biological engineering agent development.
 
FundingS (listed the recent ones due to page limitation)
 

1. PI., Fuzhou University Start-up fund ￥10 million (01/2012-present)  

 

2. PI. Project “Interference by nitric oxide with adhesion of circulating tumor cells to vascular endothelium” (01/2013-12/2016). Natural Science Foundation of China (NSFC) Grant# 81273548. ￥650,000.

 

3. PI. 973 program of Ministry of Science and Technology of China (Grant# 2015CB931804); Project title: Lung cancer personal treatments evaluation based on in vivo lung carcinoma classification. 01-2015/ 12/31/2019; ￥5.25 millions.

 

4. NSFC program: Frontier researches on bioactive materials extracted from Murraya paniculata widely-grown in Fujian and Taiwan, their mechanism of actions and drugability used for cancer metastasis chemoprevention after operation. Grant# U1505225; ￥2.58M, 2016.01 to 2019.12

 

5. NSFC-RFBR international program “Multi-circular aptamers targeting FZD and EpCAM to restrain TNBC circulating tumor cells in vivo” Grant# 8191101493; ￥1M, 2019.01-2022.12

 
AWARDS/ HONORS
 

• “Life & Chemistry Research Award” WuXi AppTec Pharm. Award (2020; China Top Pharm. Award)
• The Most Cited Chinese Researchers Award selected by Scopus/ Elsevier for exceptional research performance in the field of Chemistry and Engineering Tech. (2020)
• World’s Top 2% Scientist in 2020 in Pharmacology & Pharmacy selected by Scopus/Elsevier.
• Nanjing Metropolis Top Entrepreneurship Award (2019)
• The Most Cited Chinese Researchers Award selected by Scopus/ Elsevier for exceptional research performance in the field of pharmacology and pharmacy (2014- 2019)
• Fuzhou University Top Prize for Postgraduate Teaching Achievements (2017)
• China Internet-plus Innovation and Entrepreneurship Competition Gold Prize for Outstanding Mentoring University Students (in 2017, 2018; The China annual university top competition)
• China Industry-University-Research Institute Cooperation for Innovation (individual) Award (2017)
• “Honorable Fuzhou City Citizen” (2014) awarded by the Fuzhou City Standing Committee for his outstanding contributions to the promotion of the development and expansion of international exchanges and cooperation to make the economic and social prosper of Fuzhou City, China.
• The Fujian Science & Technology Innovation Leadership Award (2011).
• American Association of Pharmaceutical Scientists Leadership Awards (2012)
• Fellow of American Association of Pharmaceutical Scientists (2011)
• National Cancer Institute Merit Award for outstanding pharmaceutical development (2004; NCI/USA)
• Yangtze River (Changjiang) Distinguished Scholar (1999)
• First-class Army Science and Technology Progress Award (1997)

 
PUBLICATIONS (selected from total 220 SCI papers as of 05/2021; Citation information is obtained from google scholar):
 

1. Jia, L, Furchgott R.F. Inhibition by sulfhydryl compounds of vascular  relaxation induced by nitric oxide and endothelium-derived relaxing factor  J. Pharmacol. Exp. Ther. 1993; 267:371-378. (109 citations) 

 

2. Jia, L., Bonaventura, C., Bonaventura, J. and Stamler, J. S.: S-nitrosohemoglobin:  a dynamic activity of blood involved in vascular control.   Nature    1996; 380: 221-226.  IF42.35 (1889 citations) This impactful work reported first discovery of endogenous S-nitrosohemoglobin and revealed its biological functions.

 

3. Simon, D.I., Mullins, M.E., Jia, L., Gaston, B., Singel, D. J., Stamler, J.S.: Polynitrosylated Proteins: Characterization, bioactivity and functional consequences.  Proc. Natl. Acad. Sci. U.S.A.  1996; 93: 4736-4741.  IF9.8. (218 citations)

 

4. Stamler, J.S., Jia, L., Eu, J.P., McMahon, T.J., Demchenko, I.T., Bonaventura, J., Piantadosi, C.A.: Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient.  Science. 1997; 276: 2034-2037. IF31.48 (1201 citations) Jia made significant contributions to clarify S-nitrosohemoglobin functions. 

 

5. Jia*, L. Wong, H. In vitro and in vivo assessment of cellular permeability and pharmacodynamics of S-nitrosylated captopril, a nitric oxide donor. Br. J. Pharmacol. 2001; 134:1697-1704. IF6.3; (27 citations)

 

6. Jia,* L. Wong, H. Cerna, C. Weitman, S. Effect of nanonization on absorption of 301029: Ex vivo and in vivo pharmacokinetic correlations determined by LC/MS. Pharm. Res. 2002; 19:1091-1096.  IF3.95 (110 citations). This early work demonstrates that nanonization enhances oral bioavailability.  

 

7. Jia,* L. Wong, H. Wang, Y. Garza, M. Weitman, S. Carbendazim: Disposition, cellular permeability, metabolite identification and pharmacokinetic comparison with its nanoparticle. J. Pharm. Sci. 2003; 92:161-172. IF3.007; (82 citations)

 

8. Jia,* L. Schweizer, J. Cerna, C. Wong, H. Revilla, M. Effect of NO on cytotoxicity of Taxol: enhanced Taxol transcellular permeability. Biochem. Pharmacol. 2003; 66: 2193-2199.  IF4.65; (31 citations)

 

9. Jia,*L. Tomaszewski,J., Hanrahan, C. Coward, L. Noker, P. Gorman, L. Nikonenko, B. Protopopova, M. Pharmacodynamic and pharmacokinetic characteristics of SQ109, a new diamine-based antitubercular drug. Br. J. Pharmacol. 2005; 144, 80-87. IF6.5 (265 citations) This private-public partnership work showed a novel anti-TB drug with clear drug delivery profile. 

 

10. Jia,* L. Coward, L. Gorman, L. Noker, P. Tomaszewski, J. Pharmacoproteomic effects of isoniazid, ethambutol, and N-Geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv.  J. Pharmacol. Exp. Ther. 2005; 315, 905-911.  IF3.855 (51 citations)

 

11. Jia,*L. Nanoparticle formulation Increases oral bioavailability of poorly soluble drugs: experimental evidences, theory, and approaches. Curr. NanoScience 2005; 1:(3) 237-243. IF1.422  (87 citations)

 

12. Jia,*L, Noker, PE, Coward, L. Gorman, G. Protopopova, M, Tomaszewski, JE. Interspecies pharmacokinetics and in vitro metabolism of SQ109   Br. J. Pharmacol. 2006; 147:476-85.  IF5.6 (112 citations) This work shows interspecies differences in SQ109 drug delivery and in vitro metabolism.

 

13. Jia,*L, Zhu, Y., Wang, Y., Wu, W., Dong, Y.C., Zhang, R., Fu, L., Bi, H., Tam, J. Harmonising GLP rules in the US and China: The globalisation of the pharma industry means China and the US need bilateral agreements on GLP regulations. The Regulatory Affairs Journal  2007; 18(3):147-152.

 

14. Liu, X.D., Jia*,L. The conduct of drug metabolism studies considered good practice (I): analytical systems and in vivo studies. Curr. Drug Metab.  2007; 8: 815-821. IF5.2  (64 citations)

 

15. Jia,*L, Liu, X.D. The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr. Drug Metab.  2007; 8: 822-829. IF5.2 (258 citations) This highly-cited review summarizes GLP-guided drug metabolism practices.  

 

16. Jia,*L, Schweikart, K., Tomaszewski, J., Reed, J., Ames, M, Page, J., Noker, P., Munn, D. Toxicology and pharmacokinetics of 1-methyl-D-tryptophan: absence of toxicity due to saturating absorption.   Food Chem. Toxicol. 2008; 46: 203-211. IF3 (84 citations)

 

17. Liang, X.J., Chen, C.Y., Zhao, Y.L., Jia, L., Wang, P.C. Biopharmaceutics and Therapeutic Potential of Engineered Nanomaterials.  Curr. Drug Metab. 2008; 9(8): 697-709.  IF5.113 (143 citations)

 

18. Kitada, S., Kress, C.L., Krajewska, M., Jia, L., Pellecchia, M., Reed, J.C. Bcl-2 antagonist ApoGossypol (NSC736630) displays single-agent activity in Bcl-2 transgenic mice and has superior efficacy with less toxicity compared to Gossypol (NSC19048). Blood, 2008; 111: 3211-3219.  IF9.775  (134 citations)

 

19. Jia,*L. Zhao, YQ. Current Evaluation of Ginseng (I): Etymology, Pharmacognosy, Phytochemistry, Market and Regulations. Curr. Med. Chem. 2009; 16: 2475-2484. IF5.9 (263 citations) This highly-cited article summarized phytochemistry and market of ginseng products.

 

20. Jia*,L, Zhao, YQ. Liang, X.J. Current Evaluation of the Millennium Phytomedicine― Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine.  Curr. Med. Chem. 2009; 16: 2924-2942. IF5.9 (267 citations) This highly-cited article collected 108 major compounds found in ginseng.

 

21. Liang, XJ., Meng, H., Wang, Y., He, H., Meng, J., Lu, J., Wang, P., Zhao, YL., Gao, X., Sun, B., Chen, CY., Xing, GM., Shen, DW., Yin, JJ., Gottesman M., Jia, L.  Metallofullerene Nanoparticles Overcome Tumor Resistance to Cisplatin by Reactivating Endocytosis. Proc. Natl. Acad. Sci. U.S.A. 2010; 107: 7449-7454. IF9.8 (248 citations) This highly-cited work reported safe and effective metallofullerene nanoparticles.

 

22. Tan, J.J., Cong, X.J., Hu, L.M., Wang, C.X., Jia, L, Liang, X.J. Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. Drug Discovery Today 2010; 15:186-197. IF6.8  (73 citations)

 

23. Jia, L*, Zhao, YL, Liang, XJ. Fast Evolving Nanotechnology and Relevant Programs and Entities in China. Nano Today 2011; 6: 6-11.  IF18.5 (25 citations)

 

24. Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, JM., Ames, M., Jia, L., et al. Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas. Cancer Res. 2011; 71:5626-34. IF8.928 (245 citations)

 

25. Jia, X., Jia,*L. Nanomaterials improve biological functions of photosensitizers used for photodynamic therapy. Curr. Drug Metab. 2012; 13: 1119-22. IF5.113 (69 citations)

 

26. Shao, J., Xue, JP, Dai, YC, Liu, H, Jia*, L, Chen, N, Huang, L. Inhibition of human hepatocellular carcinoma HepG2 by phthalocyanine photosensitizer Photocyin: ROS production, apoptosis, and cell cycle arrest. Eur. J. Cancer. 2012; 48: 2086-96. IF5.536 (49 citations)

 

27. Zhang, F, Xie, JP, Shao, JW., Jia*, L. Compilation of 222 Drugs’ Plasma Protein Binding Data and Guidance for Study Designs. Drug Disc. Today 2012; 17:475-495. IF6.828 (152 citations) This article summarized that more than 50% drugs have plasma protein binding rate >90%

 

28. Jia,*L. Lu, Y., Shao, J., Liang, XJ., Xu Y. Nanoproteomics: a new spin from emerging links between nanotechnology and proteomics. Trends Biotech. 2013; 31:99-107. IF11.96 (30 citations).

 

29. Shao, JW., Dai, Y., Zou, WT., Xue, JP., Ye, J., Jia*, L. Intracellular distribution and mechanisms of actions of photosensitizer Zinc (II)-phthalocyanine solubilized in Cremophor EL against human hepatocellular carcinoma HepG2 cells. Cancer Lett. 2013; 330: 49-56.  IF6.2 (55 citations).

 

30. Gao, Y. Xie, J., Chen, H., Gu, S., Zhao, R., Shao, J., Jia*, L. Nanotechnology-based intelligent drug design for cancer metastasis treatment. Biotech Adv. 2014; 32:761-777. IF11.6 (140 citations) This highly-cited work illustrates how to design and engineer intelligent nanodrugs.

 

31. Jiang, Z., Shao, J., Ting, Y., Wang, J., Jia*, L. Pharmaceutical development, composition and quantitative analysis of phthalocyanine as the photosensitizer for cancer photodynamic therapy. J. Pharm. Biomed. Anal. 2014; 78：98-104. IF 2.829 (104 citations).

 

32. Gao, Y., Shao, J., Jiang, Z., Chen, J., Gu, S., Yu, S., Zheng, K., Jia,* L Drug enterohepatic circulation and disposition: constituents of systems pharmacokinetics. Drug Disc. Today 2014; 19:326-340; IF6.89 (cited 50).

 

33. Wang, J., Jiang, Z., Shao*, J., Ou, M., Li, Y., Lu, Y., Xiang, L., Lin, L., Dai, Y., Jia, L*, Synergism of ursolic acid derivative with 2-deoxy-D-glucose to preferentially induce tumor cell death by dual targeting of apoptosis and glycolysis. Sci. Reports 2014, 4:5006; IF5.078  (50 citations)

 

34. Wang, J., Chen, J., Wan, L., Shao*, JW., Lu, Y., Zhu, Y., Ou, M., Yu, SH., Chen, HJ., Jia*, L. Synthesis, spectral characterization and pharmacological evaluation of metapristone, a novel cancer metastatic chemopreventive derived from RU486. AAPS J. 2014; 16:289-98. IF4.905  (40 citations)

 

35. Chen, JZ., Wang, JC., Shao, JW., Gao, Y., Xu, JG, Yu, SH., Liu, ZH., Jia,*L. The Unique Pharmacological Characteristics of Mifepristone: from Terminating Pregnancy to Preventing Cancer Metastasis. Med. Res. Rev. 2014; 34：979–1000. IF 9.583  (40 citations)

 

36. Lu, Y., Yu, T., Liang, H., Wang, J., Xie, J., Shao, J., Gao, Y., Yu, S., Chen, S., Wang, L., Jia,*L. Nitric oxide inhibits hetero-adhesion of cancer cells to endothelial cells: restraining circulating tumor cells from initial metastatic cascade.  Sci. Reports 2014; 4: 4344 IF5.078.  (66 citations)

 

37. Xie, JJ, Zhao, R, Gu, S., Dong, H., Wang, J., Lu, Y., Sinko, PJ., Yu, T., Xie, FW., Wang, L., Shao*, J., Jia, *L The architecture and biological function of dual antibody-coated dendrimers: enhanced control of circulating tumor cells and their hetero-adhesion to endothelial cells for metastasis prevention. Theranostics 2014; 4: 1250-63; IF8.9. (32 citations)

 

38. Xie, JJ., Lu, Y., Dong, HY., Zhao, RL., Chen, HN., Shen, WY., Sinko, PJ., Zhu, Y., Wang, JC., Shao, JW., Gao, Y., Jia*, L. Enhanced specificity in capturing and restraining circulating tumour cells with dual antibody-dendrimer conjugates. Adv. Funct. Mater. 2015, 25, 1304–1313 IF13 (38 citations)

 

39. Yu, S., Yang, XT., Zhu, Y., Xie, FW., Lu, YS., Yu, T., Yan, CC., Shao, J., Gao, Y., Mo, F., Cai, GN., Sinko, PJ., Jia,*L. Systems biological pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex. Sci. Rep. 2015; 5:7830. IF5.078 (25 citations)

 

40. Xie, J., Dong, HY., Chen, HN., Zhao, R., Sinko, JP., Shen, WY., Wang, JC., Lu, YS., Yang, XT., Xie, FW., Jia,*L. Exploring cancer metastasis prevention strategy: interrupting adhesion of cancer cells to vascular endothelia of potential metastatic tissues by antibody-coated nanomaterial J. Nanobiotechnology, 2015; 13:9,1-13.  IF6.015  (11 citations)

 

41. Xie J, Wang, J., Chen H, Shen, WY., Sinko JP., Dong H., Zhao R., Lu Y., Zhu YW., Jia,*L. Multivalent Conjugation of Antibody to Dendrimers for the Enhanced Capture and Regulation on Colon Cancer Cells. Sci. Reports 2015; 5: 9445. IF5.078  (25 citations)

 

42. Dong, HY.,#, Yang,X.,#, Xiang,L., Li,YF., Ou, M., Chi, T., Liu, ZH., Shao*, JW., Jia*, L. UP12, a novel ursolic acid derivative with potential for targeting multiple signaling pathways in hepatocellular carcinoma. Biochem. Pharmacol. 2015; 93:151-162 IF5.2. (43 citations)

 

43. Xu, J., Dong, H., Shen, W., He, S., Li, H., Lu, Y., Wu, Z.-S*., Jia,*L. New molecular beacon for p53 gene point mutation and significant potential in serving as the polymerization primer. Biosens. Bioelectron. 2015; 66:504-511. IF 6.451.  (23 citations)

 

44. Gao*, Y., Li, ZR., Xie, XD., Wang, CQ.,You, J., Mo, F., Jin, B., Chen, JZ., Shao, JW., Chen, HJ., Jia*, L. Dendrimeric anticancer prodrugs for targeted delivery of ursolic acid to folate receptor-expressing cancer cells: synthesis and biological evaluation. Eur. J. Pharm. Sci. 2015; 70:55-63. IF3.01.  (65 citations)

 

45. Lu, Y., Liang, HY., Yu, T., Xie, JJ., Chen, SM., Dong, HY., Sinko, PJ., Lian, S., Xu, JG., Wang, JC., Yu, SH., Shao, JW., Yuan, B., Wang, L., Jia,*L. Isolation and Characterization of Alive Circulating Tumor Cells by Immunomagnetic Negative Enrichment Coupled with Flow Cytometry. Cancer 2015; 121:3036-45. IF4.9 (56 citations) This early work reported how to separate and characterize circulating tumor cells in blood.

 

46. Wan#, LY, Dong#, HY, Xu, H., Zhu, YW., Lu, Y., Ma, J., Wang, JC., Xie, JJ., Xu, B., Gao, Y., Shao, JW., Jia,* L Aspirin, lysine, mifepristone and doxycycline combined can effectively and safely prevent and treat cancer metastasis: prevent seeds from gemmating on soil. Oncotarget. priority publication; 2015; 6(34):35157-72；IF6.63.  (34 citations)

 

47. Xie, J., Yu, G., Zhao, R., Sinko, P., Gu, S., Wang, J., Li, Y., Lu, Y., Yu, S., W, Lie., Chen, S., Shao, J., Jia,* L. Ex vivo and in vivo capture and deactivation of circulating tumor cells by dual-antibody-coated dendrimers. J. Control Release. 2015; 209:159-69. IF7.705.  (18 citations)

 

48. Dong, HY., Wu* ZS, Xu, JG., Ma, J., Zhang, HJ., Wang, J., Shen, WY., Xie, JJ., Jia,*L Novel multifunction-integrated molecular beacon for the amplification detection of DNA hybridization based on primer/template-free isothermal polymerization. Biosens. Bioelectron. 2015; 72:182-90. (17 citations)

 

49. Xu JG., Wu* ZS., Shen, WY., Xu, H, Li, LH., Jia,* L. Cascade DNA nanomachine and exponential amplification biosensing. Biosens. Bioelectron. 2015; 73:19-25. IF 6.451. (32 citations)

 

50. Gao§,Y., Gu§, S., Zhang, Y., Xie, XD., Yu, T., Lu, Y., Zhu, Y., Chen, WG., Zhang, H., Dong, HY., Sinko, PJ., Jia,*L. The architecture and function of monoclonal antibody-functionalized mesoporous silica nanoparticles loaded with mifepristone: repurposing abortifacient for cancer metastatic chemoprevention. Small. 2016; 12:2595-608. IF8.9. (33 citations)

 

51. Dong, HY#, Gao, Y#, Sinko, PJ., Wu, ZS., Xu, JG., Jia,*L. The nanotechnology race between China and the United States. Nano Today. 2016; 11:7-12. IF18 (27 citations) 

 

52. Gao Y., Jin B., Shen WY., Sinko PJ., Xie XD., Zhang, HJ., Jia* L. China and the United States- global partners, competitors and collaborators in nanotechnology development. Nanomedicine: Nanotechnology, Biology, and Medicine. 2015; 12:13-19. IF6.5  (23 citations)

 

53. Xu, JG., Qian, J., Li, H., Wu,* ZS., Shen, W., Jia,*L.  Intelligent DNA machine for the ultrasensitive colorimetric detection of nucleic acids. Biosensors and Bioelectronics, 2016,75:41-47  (21 citations)

 

54. Xu, JG., Li, HN., Wu ZS*., Qian, J., Xue, C. Jia,*L. Double-stem Hairpin Probe and Ultrasensitive Colorimetric Detection of Cancer-related Nucleic Acids. 2016; 6(3): 318-327. Theranostics. IF8.85 (23 citations)

 

55. Xie, XD., Li, FQ., Zhang, HJ., Lu, YS., Lian, S., Lin, H., Gao*, Y., Jia,*L. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery. Eur. J. Pharm. Sci. 2016; 83:28-35. IF3.35  (103 ESI-high citations) This ESI-highly-cited paper reported how the engineered antibody-aptamer nanoparticle conjugates could precisely target colon cancer.

 

56. Dong, HY., Ma, J. Wang, J., Wu,* ZS., Sinko, PJ.,  Jia,*L. A biofunctional molecular beacon for detecting single base mutations in cancer cells. Mol Ther Nucleic Acids. 2016; 5:e302. IF6.4. 13 citations

 

57. Yu,#SH*, Yan#, CC, Yang#, XT., He, SD., Liu, J., Qin, CT., Huang, CZ., Lu, YS., Tian, ZQ., Jia,* L. Pharmacoproteomic analysis reveals that metapristone (RU486 metabolite) intervenes E-cadherin and vimentin for cancer metastasis chemoprevention. Sci. Rep. 2016; 6, 22388. IF5.58 (20 citations)

 

58. Xu, JG., Wu*, ZS., Wang, ZM., Li, HN., Le, JQ.,  Jia* L. Two-wheel drive-based DNA nanomachine and its sensing potential for highly sensitive analysis of cancer-related gene.  Biomaterials. 2016; 100:110-117. IF8.557  (25 citations)

 

59. Xu, JG., Wu, *ZS., Li, HN., Wang, ZM., Le, JQ., Zheng, TT., Jia,*L. Dual-cyclical nucleic acid strand-displacement polymerization based signal amplification system for highly sensitive determination of p53 gene.  Biosens. Bioelectron. 2016, 86: 1024–30. (16 citations)

 

60. Li, HN. Xu, JG., Wang ZM., Wu,# ZS., Jia,*L. Increasingly branched rolling circle amplification for the cancer gene detection. Biosens. Bioelectron. 2016; 86: 1067-73.  (16 citations)

 

61. Xu, J., Wu,*ZS., Wang, ZM., Le, JQ., Zheng, TT., Jia,*L. Autonomous assembly of ordered metastable DNA nanoarchitecture and in situ visualizing of intracellular microRNAs. Biomaterials. 2017; 120:57-65. IF10.3  (19 citations)

 

62. Dong, HY., Han, L., Wu, ZS., Zhang, T., Xie, JJ., Ma, J., Wang, J. Li, T., Gao, Y., Shao, JW., Sinko, P., Jia*,L Biostable aptamer rings conjugated to target two biomarkers on circulating tumor cells in vivo with great precision.  Chem. Mater. 2017, 29:10312–10325. IF10.2 (25 citations)

 

63. Xu, J, Wu, ZS.*, Shen, WY., Le, JQ., Zheng, TT., Li, H., Jia,*L. Programmable nanoassembly consisting of two hairpin-DNAs for p53 gene determination. Biosens. Bioelectron. 2017; 94: 626–631. IF9.518 (3 citations)

 

64. Gao, Y., Xie, XD., Li, FQ., Lu, YS., Li, T., Lian, S., Zhang, YY., Zhang, H., Mei, H., Jia*L The novel nanomissile targeting two biomarkers and accurately bombing CTCs with doxorubicin. Nanoscale 2017; 9:5624-5640 IF7.367 (13 citations)

 

65. Zheng N, Chen J, Li T, Liu W, Liu J, Chen H, Wang J, Jia*L. Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention. Mol Carcinog. 2017 56(8):1896-1908. IF3.851 (15 citations)

 

66. Li, FQ., Mei, H., Gao*,Y., Xie, XD., Nie, HF., Li, T., Zhang, HJ., Jia*L. Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer. Biomaterials. 2017; 145：56-71. IF10.3 (73 citations) This paper reported the engineered aptamer complexes that could reverse cancer drug resistance.

 

67. Dong, HY, Han, LY., Wang, J., Xie, JJ., Gao, Y., Xie, FW, Jia,*L, In vivo inhibition of circulating tumor cells by two apoptosis-promoting circular aptamers with enhanced specificity. J. Control Release 2018; 280: 99-112. IF7.87 (6 citations).

 

68. Zheng, N., Liu, WQ, Chen, JH, Li, BF., Liu, J., Shi, Q., Wang, JC., Gao, Yu., Shao, JW., Jia,*L. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer. Mol Carcinog. 2019; 58:144-155 (5 citations) It is the top 10% of most downloaded papers in Mol. Carcinog. announced by the Journal.

 

69. Wang, J., Dong, HY., Han, LY., Zhang, T., Lin, M., Wang, JH., Xu, H., Wu, ZS., Jia*L. Immunomagnetic antibody plus aptamer pseudo-DNA nanocatenane followed by rolling circle amplication for highly-sensitive CTC detection. Biosens. & Bioelectron. 2018; 122: 239-46. IF9.51 (6 citations)   

 

70. Zheng, TT., Gao, Y., Deng, XX., Liu, HB., Liu, J., Liu, R., Li, YL., Jia*L Differences and similarities between graphene oxide and graphdiyne oxide in physicochemistry biology and cytotoxicity. ACS Appl Mater Interfaces. 2018; 10:32946-54, IF8.097. (ACS Editors’ choice article) (6 citations)

 

71. Zhou, YY., Lin, M., Wang, J., Chen, F., Li, FY., Chen, WG., Han, LY., Wang, CH., Chen, JM., Shao, JW., Jia,*L. A Novel S-Nitrosocaptopril Monohydrate for Pulmonary Arterial Hypertension: H2O and –SNO Intermolecular Stabilization Chemistry. Free Radical Biol. Med. 2018; 129: 107-15. IF6.02

 

72. Lian, S., Xie, RZ., Ye, YY., Xie, XD., Li, SH., Lu, YS., Li, BF., Cheng, YL. Katanaev, VL., Jia,*L  Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release. EBioMedicine 2019; 42: 281–295. IF6.683.  (35 citations)

 

73. Xie, XD., Nie, HF., Zhou, Y., Lian, S., Mei, H., Lu, YS., Dong, HY., Li, F., Li, T., Li, BF., Wang, J., Lin, M., Wang, CH., Shao, JW., Gao, Y., Chen, JM., Xie, FW., Jia,*L Eliminating blood oncogenic exosomes via the small intestine with aptamer-functionalized nanoparticles. Nat. Comm. 2019; 10:5476 (IF12) (22 citations) This work firstly demonstrated that it is possible to eliminate blood biohazards into small intestines. 

 

74. Liu, J. Zheng, JX., Zhang, DD., Cao, DR., Xing, Z., Li, BF., Jia,*L. Molybdenum disulfide-based hyaluronic acid-guided multifunctional theranostic  nanoplatform for magnetic resonance imaging and synergetic chemo-photothermal therapy J. Colloid Interface Sci. 2019; 548:131-144；IF6.363 (2 citations)

 

75. Nie, HF, Xie, XD, Zhang, DD, Zhou, Y, Li, BF, Li, FQ, Li, FY, Cheng, YL., Mei, H., Meng,*H., Jia,*L. Use of lung-specific exosomes for miRNA delivery in non-small cell lung cancer. Nanoscale, 2020;12:877-87. IF6.97 (38 ESI-high citations) This ESI-highly-cited paper reports the new functions of the engineered exosomes.

 

76. Liu, J., Zheng, JX., Nie, H., Chen, HN., Li, BF., Jia,*L. Co-delivery of erlotinib and doxorubicin by MoS2 nanosheets for synergetic photothermal chemotherapy of cancer. Chem. Eng. J. 2020; 381: 122541. IF10.6

 

77. Le, JQ., Xu, JG., Zheng, JX., Li, BF., Zheng, TT., Lu, YS., Shen, WY., Kudryavtseva, AV., Katanaev, VL., Shao, JW., Jia,*L. One nanometer self-assembled aptamer-DNA dendrimers carry 350 doxorubicin: super-stability and intra-nuclear DNA comet tail. Chem. Eng. J. 2020; 388:124170. IF10.65

 

78. Xie, XD#, Lian, S#, Zhou, Y., Li, B., Lu, YS., Yeung, I., Jia*,L Tumor-derived exosomes can specifically prevent cancer metastatic organotropism. J. Control Release IF7.727 2021; 331:404-415.

 

79. Zhong C, Yang J, Lu Y, Xie H, Zhai S, Zhang C, Luo Z, Chen X, Fang X, Jia,*L. Achyranthes bidentata polysaccharide can safely prevent NSCLC metastasis via targeting EGFR and EMT. Signal Transduct Target Ther. 2020; 5(1):178-181. IF14.

 

80. Deng, XX, Xie, HZ, Lin, M, Liu, HB., Li, YL., Lu, YS., Wang, J., Li, YM., Zhong, CL., Xu, H., Jia,*L Graphdiyne Oxide and Graphene Oxide Sense Monovalent Cations Differently: the Alkyne and Alkene Physicochemistry. Nano Today. 38: 101141; DOI: 10.1016/j.nantod.2021.101141 IF16;

 
Teaching Experience
 

1. Edited Textbook “Multidisciplinary knowledge and skills for new drug development”. Jia, L., ed., ISBN 978-7-03-056630-0; Science Publisher, Beijing, China, 2018.
2. Mentored 45 graduate students, some of them now work at Universities or Government agency at Assistant or Associate Professor levels.